CKD patients with anemia were treated with erythropoietin (EPO)-stimulating agents (21.6%, p = 0.001) and supplemental iron therapy (36.3%, p = 0.001), and showed significantly lower ferritin levels (p < 0.001) than those without anemia. This evidence concerns the gene EPO and anemia (phenotype).